Pharmala Competitors

Summary

PMBHFDelisted Stock

0.25 0.00 0.00%

Pharmala Biotech Holdings competes with Nabors Industries, Where Food, SNDL, Tyson Foods, and Lifevantage; as well as few others. Analyzing Pharmala Biotech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Pharmala Biotech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Pharmala Biotech competition on your existing holdings.

Specify up to 10 symbols:

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Pharmala Biotech. Your research has to be compared to or analyzed against Pharmala Biotech's peers to derive any actionable benefits. When done correctly, Pharmala Biotech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Pharmala Biotech Holdings.

Pharmala Biotech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Pharmala Biotech and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Pharmala and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Pharmala Biotech Holdings does not affect the price movement of the other competitor.

	NBR	WFCF	SNDL	TSN	LFVN	COCO	PDS
NBR		-0.05	0.07	-0.23	0.17	0.18	0.17	NBR
WFCF	-0.05		-0.5	0.54	0.76	0.69	-0.32	WFCF
SNDL	0.07	-0.5		-0.44	-0.4	-0.42	-0.11	SNDL
TSN	-0.23	0.54	-0.44		0.41	0.64	0.21	TSN
LFVN	0.17	0.76	-0.4	0.41		0.85	-0.36	LFVN
COCO	0.18	0.69	-0.42	0.64	0.85		-0.01	COCO
PDS	0.17	-0.32	-0.11	0.21	-0.36	-0.01		PDS
	NBR	WFCF	SNDL	TSN	LFVN	COCO	PDS

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

COCO	+ 0.85	LFVN
LFVN	+ 0.76	WFCF
COCO	+ 0.69	WFCF
COCO	+ 0.64	TSN
TSN	+ 0.54	WFCF
LFVN	+ 0.41	TSN

High negative correlations

SNDL	- 0.5	WFCF
TSN	- 0.44	SNDL
COCO	- 0.42	SNDL
LFVN	- 0.4	SNDL
PDS	- 0.36	LFVN
PDS	- 0.32	WFCF

Risk-Adjusted Indicators

There is a big difference between Pharmala Pink Sheet performing well and Pharmala Biotech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pharmala Biotech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
NBR	2.92	(0.03)	(0.01)	0.06	3.40	(3.08)	6.27	(5.59)	15.91
WFCF	1.37	0.19	0.06	0.88	1.62	(1.59)	3.34	(2.99)	12.53
SNDL	1.86	(0.15)	0.00	0.33	0.00	0.00	3.65	(3.62)	24.46
TSN	0.86	(0.04)	0.00	(0.08)	0.00	0.00	1.61	(1.92)	9.06
LFVN	3.17	0.82	0.23	10.00	2.88	(3.80)	7.93	(5.43)	18.13
COCO	1.44	0.46	0.23	1.71	1.27	(1.62)	3.72	(2.66)	11.39
PDS	1.73	(0.10)	0.00	(0.13)	0.00	0.00	3.44	(3.75)	11.68

Unable to evaluate fundamental data of Pharmala Biotech Holdings at this time. Please try again later

All Fundamental Data

Pharmala Biotech Competitive Analysis

The better you understand Pharmala Biotech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Pharmala Biotech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Pharmala Biotech's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	PMBHF	NBR	WFCF	SNDL	TSN	LFVN	COCO	PDS
	0.00 0.25 Pharmala	2.59 65.38 Nabors	1.30 12.46 Where	2.20 1.78 SNDL	1.18 60.48 Tyson	6.23 16.04 Lifevantage	0.14 36.72 Vita	1.60 60.35 Precision
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Not too volatile	Risky	Very steady	Slightly risky	Very steady	Very steady
Market Performance (90 Days Performance)	Very Weak	Weak	OK	Very Weak	Very Weak	Solid	Solid	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Unknown	Below Average	Very Small	Average	Low	Low	Low	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Under Valued	Under Valued	Under Valued	Over Valued	Over Valued	Fairly Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Hold	Strong Sell	Strong Buy	Buy	Strong Sell	Strong Buy	Strong Buy
Trade Advice (90 Days Macroaxis Advice)	Not Rated	Strong Sell	Strong Hold	Strong Sell	Strong Hold	Hold	Buy	Cautious Hold
Current Ratio		1.73 X	2.24 X	6.63 X	1.81 X	1.83 X	2.99 X	1.39 X
Net Asset		5.28 B	16.29 M	1.47 B	37.1 B	60.3 M	285.68 M	3.02 B
Profit Margin		(0.05) %	0.08 %	(0.12) %	0.01 %	0.02 %	0.12 %	0.13 %
EBITDA		959.7 M	3.33 M	(99.15 M)	2.97 B	7.93 M	58.61 M	599.35 M
Operating Margin		0.09 %	0.09 %	(0.04) %	0.04 %	0.05 %	0.15 %	0.14 %
Current Valuation		2.67 B	65.63 M	380.02 M	29.59 B	199.67 M	1.93 B	1.44 B
Price To Book		3.26 X	6.96 X	0.56 X	1.17 X	7.25 X	8.26 X	0.73 X
Retained Earnings		(1.89 B)	9.74 M	(1.26 B)	18.87 B	(108.74 M)	100.74 M	(1.01 B)
Current Asset		1.48 B	5.85 M	N/A	4.89 B	42.41 M	288.6 M	561.95 M
Five Year Return		3.99 %	N/A	N/A	2.09 %	N/A	N/A	N/A
Beta		2.1	0.52	3.2	0.78	0.86	0.22	2.75
Number Of Employees		12 K	89	2.52 K	138 K	222	294	5 K
Shares Outstanding		9.55 M	5.28 M	265.56 M	285.86 M	12.53 M	56.73 M	14.07 M
Cash Flow From Operations		637.86 M	2.82 M	(16.65 M)	2.59 B	12.2 M	107.16 M	500.57 M
Annual Yield		N/A	N/A	N/A	0.03 %	0.01 %	N/A	N/A
Total Debt		3.15 B	2.8 M	167.03 M	9.79 B	13.61 M	1.22 M	992.19 M
Return On Equity		-0.0392	0.21	-0.0899	0.0447	0.15	0.27	0.16
Return On Asset		0.034	0.0984	-0.0219	0.0303	0.0601	0.15	0.054
Number Of Shares Shorted		1.4 M	15.92 K	4.77 M	5.6 M	199.59 K	6.09 M	125.58 K
Book Value Per Share		20.04 X	1.97 X	4.55 X	51.68 X	2.22 X	4.44 X	117.77 X
Current Liabilities		1.01 B	1.32 M	N/A	2.76 B	28.55 M	251.25 M	175.5 M
Total Asset		5.28 B	16.29 M	1.47 B	37.1 B	60.3 M	285.68 M	3.02 B
Debt To Equity		2.03 %	0.24 %	0.17 %	0.45 %	0.50 %	0.17 %	1.02 %
Short Ratio		4.35 X	2.55 X	1.83 X	2.08 X	2.11 X	9.57 X	1.79 X
Target Price		87.5	18.3	3.42	65.57	7.0	34.11	91.07
Last Dividend Paid		N/A	N/A	N/A	1.96	0.15	N/A	N/A
Shares Owned By Institutions		74.54 %	19.48 %	15.27 %	85.59 %	37.12 %	83.28 %	57.43 %
Market Capitalization		624.24 M	65.76 M	472.7 M	21.52 B	200.9 M	2.08 B	851.87 M
Price To Earning		(2.50) X	64.18 X	N/A	7.55 X	4.65 X	15.97 X	(6.85) X
Price To Earnings To Growth		(0.68) X	N/A	N/A	0.51 X	N/A	1.07 X	0.40 X
Price To Sales		0.21 X	2.56 X	0.52 X	0.40 X	1.02 X	4.21 X	0.44 X
Net Income		49.9 M	2.15 M	(176.55 M)	822 M	2.94 M	46.63 M	289.24 M
Earnings Per Share		(23.97) X	0.36 X	(0.30) X	2.25 X	0.32 X	1.00 X	11.54 X
Shares Owned By Insiders		5.17 %	49.30 %	0.32 %	2.55 %	16.89 %	12.83 %	2.10 %
Revenue		3.01 B	25.14 M	909.01 M	53.31 B	200.16 M	493.61 M	1.94 B
Working Capital		431.7 M	3.23 M	303.77 M	4.96 B	15.34 M	180.35 M	145.24 M
Cash And Equivalents		451.02 M	6.41 M	325.6 M	573 M	20.19 M	16.41 M	51.64 M
Cash Per Share		45.15 X	1.08 X	1.38 X	2.87 X	1.61 X	0.29 X	3.80 X
Gross Profit		987.76 M	10.47 M	140.38 M	2.66 B	170.01 M	103.36 M	492.59 M
Day Typical Price	0.25	65.8	12.07	1.78	60.66	15.64	36.62	60.68
Accumulation Distribution	N/A	0.0476	0.0947	0.0276	0.0168	0.082	0.0304	0.0279
Market Facilitation Index	N/A	3.22	1.18	0.05	1.03	1.32	1.13	1.72
Daily Balance Of Power	0.0	(0.54)	0.1356	(0.80)	(0.70)	0.7121	0.0442	(0.57)
Period Momentum Indicator	N/A	(1.74)	0.16	(0.04)	(0.72)	0.94	0.05	(0.98)
Rate Of Daily Change	1.0	0.97	1.01	0.98	0.99	1.06	1.0	0.98
Day Median Price	0.25	66.01	11.87	1.79	60.75	15.44	36.57	60.85
Price Action Indicator	N/A	(1.50)	0.67	(0.03)	(0.63)	1.07	0.18	(0.99)
Coefficient Of Variation	5099.44	5098.1	863.07	(1,546)	(15,155)	471.0	427.57	(4,341)
Mean Deviation	4.56	2.92	1.37	1.86	0.8602	3.17	1.44	1.73
Jensen Alpha	0.4422	(0.03)	0.1891	(0.15)	(0.04)	0.8197	0.4616	(0.10)
Total Risk Alpha	(1.57)	(0.39)	(0.03)	(0.57)	(0.19)	0.3372	0.2231	(0.33)
Sortino Ratio	0.0122	(0.01)	0.0622	N/A	N/A	0.2287	0.2265	N/A
Downside Variance	248.2	12.02	3.75	N/A	N/A	10.39	3.08	N/A
Standard Deviation	14.89	3.62	1.9	2.96	1.36	3.94	2.13	2.2
Kurtosis	31.48	(0.17)	2.58	8.47	8.54	(0.13)	3.87	0.6823
Potential Upside	4.17	6.27	3.34	3.65	1.61	7.93	3.72	3.44
Treynor Ratio	(0.16)	0.0597	0.8828	0.3276	(0.08)	10.0	1.71	(0.13)
Maximum Drawdown	108.92	15.91	12.53	24.46	9.06	18.13	11.39	11.68
Variance	221.85	13.1	3.63	8.78	1.84	15.55	4.52	4.86
Market Risk Adjusted Performance	(0.15)	0.0697	0.8928	0.3376	(0.07)	10.01	1.72	(0.12)
Risk Adjusted Performance	0.0237	0.0222	0.0902	(0.04)	(0.0001)	0.1621	0.1762	(0.01)
Skewness	5.01	0.1893	0.2763	(0.60)	1.18	0.3573	1.14	0.1866
Semi Deviation	6.16	3.4	1.62	N/A	N/A	2.88	1.27	N/A
Information Ratio	0.0129	(0.01)	0.0633	(0.1)	(0.08)	0.1869	0.1868	(0.07)
Value At Risk	(17.39)	(5.59)	(2.99)	(3.62)	(1.92)	(5.43)	(2.66)	(3.75)
Expected Short fall	(25.35)	(3.08)	(1.59)	N/A	N/A	(3.80)	(1.62)	N/A
Downside Deviation	15.75	3.47	1.94	N/A	N/A	3.22	1.75	N/A
Semi Variance	37.89	11.58	2.62	N/A	N/A	8.3	1.62	N/A

Pharmala Biotech Competition Performance Charts

Five steps to successful analysis of Pharmala Biotech Competition

Pharmala Biotech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Pharmala Biotech Holdings in relation to its competition. Pharmala Biotech's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Pharmala Biotech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Pharmala Biotech's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Pharmala Biotech Holdings, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Pharmala Biotech position

In addition to having Pharmala Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Convertibles Funds Thematic Idea Now

Convertibles Funds

Funds or Etfs that invest in debt that is expected to be converted into a predetermined amount of the company equity at some future date. The Convertibles Funds theme has 12 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Convertibles Funds Theme or any other thematic opportunities.

View All Next

Launch

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Consideration for investing in Pharmala Pink Sheet

If you are still planning to invest in Pharmala Biotech Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pharmala Biotech's history and understand the potential risks before investing.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Equity Valuation Check real value of public entities based on technical and fundamental data
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC